Riskpilot← Back to searchSign inGet full accessNeurokonsult Carlström AB
ABIn liquidationOrg 5567860639Luntmakargatan 70Medical specialists activities · NACE 8622Est. 20090 employees
Revenue 2025
SEK 0
EBITDA margin
—
-143% vs 2024
Equity ratio
99.5%
Financial strength
Net profit 2025
SEK 3M
+39% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -51K | -143% |
| Net profit | SEK 3M | +39% |
| Total assets | SEK 8,3M | +30% |
| Equity | SEK 8,3M | +34% |
| Employees | 0 | — |
Legal name
Neurokonsult Carlström AB
Org number
5567860639
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
15 juli 2009
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva läkarmottagning och läkarkonsultverksamhet, undervisning, kliniska läkemedelsstudier, konsultverksamhet för läkemedelsindustrin och därmed förenlig verksamhet.
Address
Luntmakargatan 70
Email
ekonomi@womax.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −22 | −24 | −19 | −21 | −51 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −22 | −24 | −19 | −21 | −51 |
| Net financials | — | — | — | 2 102 | 2 850 |
| Profit before tax | 82 | 256 | −6 | 2 128 | 2 986 |
| Tax | −19 | −57 | −0 | −7 | −31 |
| Net profit | 63 | 199 | −6 | 2 121 | 2 955 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 689 | 6 424 | 6 389 | 6 381 | 8 306 |
| Equity | 6 143 | 6 155 | 6 139 | 6 160 | 8 265 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 15 | 18 | 12 | 30 | 37 |
| Total debt | 15 | 18 | 12 | 30 | 37 |
EBITDA margin
-5100000.0%
This company
15.8%
Market median
-32278581% vs market
20212025
Equity ratio
99.5%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
35.8%
This company
18.4%
Market median
+95% vs market
20212025
Net profit margin
295500000.0%
This company
8.1%
Market median
+3648148048% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YM Liquidator | Liquidator | 2025 |
| Former (1) | ||
CB Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Deputy Board Member | 2020 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neurokonsult Carlström AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ylva Maria Blumenberg | Liquidator | 0 companies |
| Christian Bruno Carlström | Chief Executive Officer | 0 companies |
| Daniel M B Carlström Aravena | Deputy Board Member | 0 companies |